drugset / Trial / NCT03989362
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
JTX-2011-201 is a Phase 2, open label clinical study of vopratelimab (JTX-2011) and ipilimumab in adult subjects with non-small cell lung cancer (NSCLC) or urothelial cancer to evaluate safety and efficacy.
Timeline
- Start
- 2019-06-06
- Primary completion
- 2022-03-15
- Completion
- 2022-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | Intravenous |
| Subject | Vopratelimab | Monoclonal antibody | — | Intravenous |